tapimmune is developing immunotherapies for a variety of cancers designed to target both tumors and metastatic disease. the company’s next-generation technology has been engineered to overcome the deficiencies of earlier cancer vaccine approaches and has the potential to be a powerful standalone therapy or part of a leading combination regimen by complementing other approved or development-stage immunotherapeutics (i.e. checkpoint inhibitors). the company’s off-the-shelf vaccines boost patients’ immune systems to comprehensively stimulate both killer t-cells and helper t-cells to destroy cancer cells, and they are designed to work with 80% of the population. tapimmune is advancing two clinical stage t-cell vaccine candidates in multiple phase ii and phase ib/iia clinical trials for treating ovarian and breast cancers, including programs in ovarian cancer that will benefit from fda fast track and orphan disease designation. the company is working in collaboration with industry and clini
Company profile
Ticker
MRKR
Exchange
Website
CEO
Peter Hoang
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
EDUVERSE COM, GENEMAX CORP, TAPIMMUNE INC, TAPIMMUNE INC.
SEC CIK
Corporate docs
Subsidiaries
Marker Cell Therapy, Inc. • GeneMax Pharmaceuticals, Inc. • GeneMax Pharmaceuticals Canada, Inc. ...
IRS number
880277072
MRKR stock data
Latest filings (excl ownership)
8-K
Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results
25 Mar 24
8-K
Termination of a Material Definitive Agreement
1 Mar 24
8-K
Entry into a Material Definitive Agreement
26 Feb 24
8-K
Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization
8 Jan 24
8-K
Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T Relapse
11 Dec 23
8-K
Departure of Directors or Certain Officers
20 Nov 23
8-K
Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
9 Nov 23
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse
11 Sep 23
8-K
Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
14 Aug 23
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 17.47 mm | 17.47 mm | 17.47 mm | 17.47 mm | 17.47 mm | 17.47 mm |
Cash burn (monthly) | 216.06 k | 50.21 k | 1.07 mm | 2.13 mm | 375.82 k | 1.70 mm |
Cash used (since last report) | 1.29 mm | 299.09 k | 6.35 mm | 12.70 mm | 2.24 mm | 10.12 mm |
Cash remaining | 16.19 mm | 17.17 mm | 11.12 mm | 4.78 mm | 15.24 mm | 7.36 mm |
Runway (months of cash) | 74.9 | 342.1 | 10.4 | 2.2 | 40.5 | 4.3 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 31 |
Opened positions | 2 |
Closed positions | 2 |
Increased positions | 8 |
Reduced positions | 7 |
13F shares | Current |
---|---|
Total value | 8.10 bn |
Total shares | 20.77 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
New Enterprise Associates 16 | 14.46 mm | $26.90 mm |
Eastern Capital | 3.97 mm | $0.00 |
NEA Management | 1.07 mm | $4.86 bn |
Aisling Capital IV | 464.29 k | $8.64 mm |
Aisling Capital Management | 314.29 k | $1.43 bn |
Vanguard | 221.08 k | $1.00 bn |
Geode Capital Management | 60.05 k | $276.30 mm |
Wedbush Securities | 58.06 k | $264.00 k |
Renaissance Technologies | 40.25 k | $183.00 k |
Dimensional Fund Advisors | 20.28 k | $93.28 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
6 Jun 23 | Katharine Knobil | Stock Option Common Stock | Grant | Acquire A | No | No | 1.72 | 8,000 | 13.76 k | 8,000 |
6 Jun 23 | Steve Elms | Stock Option Common Stock | Grant | Acquire A | No | No | 1.72 | 8,000 | 13.76 k | 8,000 |
6 Jun 23 | Wilson John Robert | Stock Option Common Stock | Grant | Acquire A | No | No | 1.72 | 8,000 | 13.76 k | 8,000 |
10 May 23 | Vera Juan | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 1.42 | 100,000 | 142.00 k | 100,000 |
27 Feb 23 | Mythili Koneru | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 2.14 | 51,918 | 111.10 k | 51,918 |
Press releases
Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results
25 Mar 24
Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
22 Mar 24
Nimbus Therapeutics Appoints Katharine Knobil, M.D., to Board of Directors
12 Mar 24
Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for "Neldaleucel" as Nonproprietary Name for MT-601
22 Jan 24
Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization
8 Jan 24